Adaptive Biotechnologies

Adaptive Biotechnologies (formerly known as Adaptive TCR) is the pioneer and leader in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors.

Adaptive Biotechnologies develops assays for analysis and research of infectious diseases, autoimmunity, and cancer.

Adaptive Biotechnologies was founded in 2009 as Adaptive TCR and changed its name to Adaptive Biotechnologies Corporation in January 2012. The company is based in Seattle, Washington.

Adaptive Biotechnologies brings accuracy and sensitivity of our immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases.

Adaptive Biotechnologies's products include immunoSEQ, clonoSEQ, Pipeline, Cellular Therapy and Vaccines. The company also offers immunosequencing platform to laboratories around the world to drive research in cancer and other immune-mediated diseases.

 

Adaptive Biotechnologies Corporation has a strategic research agreement with Microsoft, Genetech, Sanofi and Argos Therapeutics, Inc.

 

Adaptive Biotechnologies is backed by Matrix Capital Management, Rock Springs Capital, and Viking Global Investors among others. The company has acquired Sequenta on Jan 7, 2015.

 

Adaptive Biotechnologies was valued $1.08B as of Jan 2019.

 

 

  • Year founded: 2009
  • Funding Info: $406.9M in 7 funding rounds (Last funding type: Series F)- It has also acquired Sequenta on Jan 7, 2015.
  • Yearly Revenue: $50M-$100M (2017)
  • Employee Size: 201-500
  • Business Valuation: Valued $1.08B as of Jan 02, 2019
  • City/Town: Seattle
  • State: Washington
  • Country: United States
Related businesses